STOK
Company Description
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 184.42M | 36.55M | 8.78M | 12.40M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.88M) | (88.98M) | (104.70M) | (101.07M) | (85.81M) | (52.24M) | (32.33M) | (12.52M) | (5.56M) |
| EPS | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| Free Cash Flow | 44.91M | (87.05M) | (82.68M) | (35.83M) | (68.11M) | (43.27M) | (32.69M) | (11.90M) | (5.50M) |
| FCF / Share | 0.76 | -1.61 | -1.88 | -0.92 | -1.85 | -1.29 | -1.82 | -0.51 | -0.23 |
| Operating CF | 45.59M | (86.85M) | (81.07M) | (31.87M) | (66.91M) | (42.22M) | (31.05M) | (10.96M) | (5.38M) |
| Total Assets | 418.43M | 271.56M | 228.34M | 256.07M | 238.87M | 297.93M | 228.75M | 107.54M | 2.44M |
| Total Debt | 3.01M | 4.77M | 2.06M | 2.36M | 5.04M | 1.07M | 0 | 0 | 3.00M |
| Cash & Equiv | 84.22M | 127.98M | 191.44M | 113.56M | 144.90M | 287.31M | 222.47M | 105.40M | 1.80M |
| Book Value | 352.46M | 229.02M | 159.56M | 184.85M | 217.78M | 286.08M | 224.43M | 105.07M | (1.29M) |
| Return on Equity | -0.02 | -0.39 | -0.66 | -0.55 | -0.39 | -0.18 | -0.14 | -0.12 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.23M | 1.40M | 10.63M | 13.82M | 158.57M | 22.61M | 4.89M | 4.83M | 4.22M | 2.80M | 3.31M | (2.48M) |
| Net Income | (50.00M) | (57.93M) | (38.35M) | (23.48M) | 112.88M | (10.48M) | (26.43M) | (25.70M) | (26.37M) | (26.96M) | (24.54M) | (30.65M) |
| EPS | -0.79 | -0.99 | -0.65 | -0.40 | 1.95 | -0.18 | -0.47 | -0.46 | -0.57 | -0.60 | -0.55 | -0.69 |
| Free Cash Flow | (60.94M) | (30.69M) | (30.50M) | (25.58M) | 131.68M | (23.23M) | (21.72M) | (17.52M) | (24.58M) | (20.88M) | (17.64M) | (22.64M) |
| FCF / Share | -0.97 | -0.53 | -0.52 | -0.44 | 2.28 | -0.41 | -0.39 | -0.31 | -0.53 | -0.46 | -0.40 | -0.51 |
| Operating CF | (60.58M) | (30.45M) | (30.37M) | (25.42M) | 131.83M | (23.19M) | (21.61M) | (17.48M) | (24.57M) | (20.65M) | (17.26M) | (21.80M) |
| Total Assets | 443.28M | 418.43M | 360.26M | 384.51M | 406.89M | 271.56M | 293.32M | 307.76M | 205.18M | 228.34M | 239.89M | 256.92M |
| Total Debt | 3.42M | 3.01M | 2.91M | 2.30M | 2.35M | 4.77M | 2.30M | 2.28M | 2.21M | 2.06M | 2.50M | 2.45M |
| Cash & Equiv | 155.66M | 84.22M | 83.39M | 101.47M | 274.82M | 127.98M | 150.02M | 193.48M | 178.58M | 191.44M | 189.98M | 192.06M |
| Book Value | 394.88M | 352.46M | 308.11M | 334.94M | 350.07M | 229.02M | 232.11M | 242.71M | 140.34M | 159.56M | 173.00M | 190.19M |
| Return on Equity | -0.13 | -0.16 | -0.12 | -0.07 | 0.32 | -0.05 | -0.11 | -0.11 | -0.19 | -0.17 | -0.14 | -0.16 |
